Kura Oncology Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

DB:KUR Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
18 Nov 24Sell€7,979Kathleen FordIndividual526€15.17
29 Jan 24Sell€117,936Stephen DaleIndividual7,158€16.48
29 Jan 24Sell€24,648Kathleen FordIndividual1,496€16.48
29 Jan 24Sell€33,826Teresa BairIndividual2,053€16.48
29 Jan 24Sell€38,192Thomas DoyleIndividual2,318€16.48

Insider Trading Volume

Insider Buying: KUR insiders have only sold shares in the past 3 months.


Ownership Breakdown

What is the ownership structure of KUR?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders640,4320.726%
VC/PE Firms4,368,9984.95%
Hedge Funds23,202,54526.3%
Institutions59,995,12668%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.7%.


Top Shareholders

Top 25 shareholders own 92.53% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.84%
Suvretta Capital Management, LLC
7,652,782€65.1m8.25%2.55%
9.2%
BlackRock, Inc.
7,155,417€60.9m2.72%no data
7.47%
EcoR1 Capital, LLC
5,806,871€49.4m0%1.81%
6.96%
Deerfield Management Company, L.P. Series C
5,411,571€46.1m0%0.87%
5.62%
RA Capital Management, L.P.
4,368,998€37.2m0%0.49%
5.57%
Paradigm Biocapital Advisors LP
4,331,321€36.9m-4.58%1.45%
5.41%
The Vanguard Group, Inc.
4,203,687€35.8m4.04%no data
4.55%
Avoro Capital Advisors LLC
3,541,505€30.1m0%0.45%
4.34%
BVF Partners L.P.
3,371,761€28.7m-17.4%0.97%
3.46%
Holocene Advisors, LP
2,689,456€22.9m0%0.1%
3.43%
State Street Global Advisors, Inc.
2,668,844€22.7m-7.48%no data
3.42%
Armistice Capital LLC
2,658,000€22.6m13.1%0.62%
2.52%
Deep Track Capital, LP
1,963,505€16.7m410%0.56%
2.38%
Foresite Capital Management, LLC
1,849,947€15.7m0%5.81%
2.31%
Commodore Capital LP
1,800,000€15.3m13%1.13%
2.29%
Geode Capital Management, LLC
1,780,509€15.2m2.39%no data
2.02%
Franklin Resources, Inc.
1,573,289€13.4m0.52%no data
1.83%
TCG Crossover Management, LLC
1,423,642€12.1m0%1.17%
1.72%
Artal Group S.A.
1,339,942€11.4m-26.4%0.36%
1.53%
Citadel Advisors LLC
1,188,995€10.1m17.4%0.01%
1.49%
Morgan Stanley, Investment Banking and Brokerage Investments
1,159,893€9.9m-9.21%no data
1.36%
Dimensional Fund Advisors LP
1,053,764€9.0m17.8%no data
1.35%
Assenagon Asset Management S.A.
1,052,063€9.0m-39.2%0.02%
1.29%
Tavistock Life Sciences
1,000,000€8.5m0%0.63%
1.17%
Candriam, Société En Commandite Par Actions
906,482€7.7m0%0.02%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 17:25
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kura Oncology, Inc. is covered by 21 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Jason ZemanskyBofA Global Research
Leah Rush CannBrookline Capital Markets